MedTrace Logo

ZIAGEN® Post-marketing Surveillance

NCT01205243 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 671

Last updated 2018-06-19

No results posted yet for this study

Summary

An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information.

Conditions

  • Infection, Human Immunodeficiency Virus I

Interventions

DRUG

ZIAGEN®

Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-01
Primary Completion
2015-02-01
Completion
2015-02-05

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01205243 on ClinicalTrials.gov